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Background/aim: Treatment of severe hypercapnic respiratory failure (HRF) has some challenges in patients with chronic obstructive
pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS), especially when lung protective ventilation (LPV)
strategies are required. Extracorporeal CO2 removal (ECCO2R) therapy is an emerging option to manage hypercapnia while allowing
LPV in these cases. However, further data on ECCO2R use is still needed to make clear recommendations.
Materials and methods: This study was conducted on patients admitted to intensive care unit (ICU) between January 1st, 2016 to
December 31st, 2019. The medical records were retrospectively scanned in institutional software database. Patients who received
invasive mechanic ventilation (iMV) support due to severe HRF related to COPD or ARDS were included in the analyses. Patients
were grouped according to treatment approaches as that ECCO2R therapy in addition to conventional treatments and conventional
treatments alone (controls). Groups were compared for 28-day survival, iMV duration, and length of stay (LOS).
Results: ECCO2R therapy was noted in 75 of the cases among included 395 patients (COPD n = 256, ARDS n = 139) out of scanned
1715 medical records. The survival rate of ECCO2R patients was 68% and significantly higher than 58% survival rate of controls (p =
0.025), with relative risk reduction (RRR) = 0.16, absolute risk reduction (ARR)= 0.10, number need to treat (NNT) = 10, and odds ratio
(OR) = 1.5. In addition, iMV duration (12.8 ± 2.6 vs. 17.1 ± 4.9 days, p = 0.007) and LOS (16.9 ± 4.1 vs. 18.9 ± 5.5 days, p = 0.032) were
significantly shorter than controls. Repeated measure analyses showed that LPV settings were successfully provided by 72 h of ECCO2R
therapy. Subgroup analyses according to diagnoses of COPD and ARDS also favored ECCO2R.
Conclusion: ECCO2R therapy significantly improved survival, iMV duration and LOS in patients with severe HRF due to COPD or
ARDS, and successfully provided LPV approaches. Further studies are needed to assess promising benefits of ECCO2R therapy.
Key words: Extracorporeal carbon dioxide removal, ECCO2R, hypercapnic respiratory failure, artificial membranes, survival, intensive
care

1. Introduction
Hypercapnic respiratory failure is defined as a condition
that plasma pH < 7.35 and partial arterial carbon dioxide
(CO2) pressure (PaCO2) > 49 mmHg [1]. In more severe
cases (pH < 7.25 and PCO2 > 60 mmHg), when persisted
against attempts of medical therapy and noninvasive
ventilation, invasive mechanical ventilation (iMV) support
and intensive care unit (ICU) admission is required [1,2].
Severe hypercapnia, whether associated with chronic
obstructive pulmonary disease (COPD) or acute respiratory
distress syndrome (ARDS), is an independent risk factor
for patient mortality [3]. In addition, iMV support, used in
treatment of severe hypercapnia, has its own consequences
such as, ventilatory associated pneumonia, ventilatorinduced lung injury (VILI), extubation failure, prolonged
intubation, and iMV dependence. In recent decades,

the lung protective ventilation (LPV) concept (low
tidal volume and pressure-limited ventilation) has been
presented with more favorable outcomes than traditional
ventilation approaches in patients with respiratory failure
[4]. LPV has been reported to decreased VILI, facilitated
extubation, and improved clinical outcomes [5].
However, LPV has an undesired consequence,
progressing hypercapnia [5]. In order to break this deadly
vicious cycle, some clinicians have proposed removing
excessive CO2 by an adjunct extracorporeal device. It was a
former concept, first introduced by Kobolow and Gattinoni
almost 40 years ago and has re-gained attention [6–8]. This
extracorporeal carbon dioxide removal (ECCO2R) technic
can be described as that CO2 is removed by an attached
artificial lung while oxygen delivered through the natural
lung. Results of preliminary studies on accountability of
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ECCO2R therapy have exceeded the clinical expectations
[2,9–14]. However, ECCO2R has been a rescue treatment
option in patients with severe hypercapnic respiratory
failure until recent years [13–16].
The later technological improvements and experiences
in ECCO2R have provided promising clinical outcomes
with lower adverse event rates [11–14,17]. Finally,
ECCO2R therapy has been recommended in the treatment
of ARDS and acute exacerbations of COPD to apply LPV
while managing hypercapnia, and to achieve targets of pH
> 7.30, respiratory rate (RR) < 20–25 breaths/min., driving
pressure (ΔP) < 14 cm H2O and plateau pressure (Pplat) <
25 cm H2O, by the European Consensus Report [18]. Some
prospective feasibility studies have still been recruiting
cases (i.e., the REXECOR trial - NCT02965079, the REST
trial - NCT02654327). However, further feasibility studies
and more evidence-based data are required to make
stronger recommendations.
ECCO2R has been successfully used in treatment of
patients with severe HRF for about 5 years in our ICU.
We conducted a retrospective data analyze of our patients
who were received ECCO2R therapy. The objective was
to elucidate and document favorable effects of ECCO2R
therapy against conventional treatments alone at respect
of 28-day survival, iMV duration, and ICU length-of-stay
(LOS).
2. Materials and methods
This retrospective study was conducted in Trakya
University Training and Research Hospital, in Turkey,
between October 5th–November 27th, 2020. The
approval was received from Bioethical Board of Trakya
University (no. = 2020/199–09/05). Informed consent
for “processing and publishing personal medical data for
scientific purposes” has been obtained at ICU admissions
(institutional policy) from patients or legally authorized
surrogates when patients were intubated, ventilated,
unconscious or sedated.
2.1. Case definitions
The case definitions were based on those “2016 British
Thoracic Society/Intensive Care Society (BTS/ICS)
Guideline for the ventilatory management of acute
hypercapnic respiratory failure in adults” for hypercapnic
respiratory failure, “2019 The Global Initiative for Chronic
Obstructive Lung Disease (GOLD)” for COPD and “2012
The Berlin Definition” for ARDS [1,19,20].
2.2. ECCO2R indications
According to practice instructions of our clinic, ECCO2R
therapy has been applied in patients who met all
requirements of these five-criteria; (1) persisting severe
hypercapnic respiratory acidosis (pH < 7.15) despite
optimized attempts of iMV for more than 3 h, (2) lung
protective ventilation was required but hypercapnia was
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undesirable or contraindicated, (3) no contraindications
for canulation and systemic anticoagulation, (4)
hemodynamic status was manageable, (5) the underlying
disease was reversable or no markers of poor short-term
prognosis.
2.3. ECCO2R procedure
The veno-venous decap system (Hemodec, Salerno, Italy)
with a small membrane lung (0.3 to 1.35 m2) connected in
series with a roller pump and low flow rates (< 500 mL/
min) was used for ECCO2R therapy [5,21,22]. Vascular
accesses were provided by percutaneous inserted doublelumen catheters into internal jugular or femoral vein.
Unfractionated heparin continuous infusion protocol was
used according to activated partial thromboplastin time
readings as recommended.
2.4. Patients’ selection
The medical records of patients admitted to ICU
between January 1st, 2016 to December 31st, 2019 were
retrospectively scanned in institutional software database.
Diagnoses were searched by ICD-10 codes (J96, J44, J80).
All patients who required iMV support due to hypercapnic
respiratory failure related to COPD or ARDS diagnoses
were included. Patients detected with both of COPD and
ARDS diagnoses were excluded to avoid case-mix bias in
subgroup comparisons.
2.5. Comparisons
Patients were grouped according to treatment approaches
as they were received ECCO2R therapy in addition
to conventional treatments (cases), and conventional
treatments alone and not received ECCO2R (controls).
Case and control groups were compared for 28-day
survival, iMV duration, and ICU LOS (see Figure 1). The
changes in clinical and laboratory parameters after 72 h of
procedure were also analyzed.
Finally, a strict 1:1 matching was processed to gain
a precise aspect and to re-test hypothesis. Additional
exclusion criteria were re-defined as; patients with age < 18
and 90 <, obstetrics, hematologic and oncologic diagnoses,
acute decompensated heart failure, acute coronary
syndromes, profound distributive shock, and ECCO2R
therapy less than 72 h. To assure a better comparability,
ECCO2R patients were best 1:1 matched with controls
by sequential organ failure assessment (SOFA) scores
corresponding to their disease severity status. Unmatched
control patients were excluded, while we downsized
the sample. Resulting COPDECCO2R: COPDControl and
ARDSECCO2R: ARDSControl subgroups were within compared
for survival. This matching process was presented in
Figure 2.
The operators were blinded for outcomes throughout
selection, allocation, matching, and exclusion procedures,
provided by software concealment.
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ICU Patients
(n=1715)
Excluded
(n=164)
Study sample
(n=395)

ECCO2R
(n=75)

Surv. (n=51)
Ex (n=24)

Surv. (n=187)
Ex (n=133)

Conv. Treat.
(n=320)

COPD
(n=49)

Surv. (n=32)
Ex (n=17)

Surv. (n=113)
Ex (n=94)

COPD
(n=207)

ARDS
(n=26)

Surv. (n=19)
Ex (n=7)

Surv. (n=74)
Ex (n=39)

ARDS
(n=113)

Figure 1. Study diagram representing allocations and comparisons. ICU; intensive care unit, ECCO2R;
extracorporeal CO2 removal, COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory
distress syndrome, conv. treat.; conventional treatment alone, surv.; survival.

2.6. Data collection
Patients’ sex, age, SOFA scores, total iMV duration,
ICU LOS, and 28-day survival status were collected. In
order to evaluate improvements by ECCO2R procedure;
arterial blood gas (ABG) parameters (pH, PaCO2, PaO2)
and ventilatory parameters (P/F ratio: PaO2/FiO2 ratio,
PEEP; positive end expiratory pressure, Pplat, ΔP[driving
pressure] = Pplat - PEEP, Tv/PBW; tidal volume/predicted
body weight) were noted at the initiation (t = 0) and at the
72nd hours of therapy (t = 72). Clinical (RR; respiratory
rate, HR; heart rate, MAP; mean arterial pressure) and
laboratory parameters (hemoglobin, PLT, PT-INR,
aPTT-ratio) were also collected to detect any probable
deteriorations. Total ECCO2R duration, the mean pump
flow and sweep gas flow rates were recorded.
Any severe adverse effect related to ECCO2R procedure
(worsening hypoxemia, hemolysis, anti-coagulation or
canula related bleeding, hematoma, heparin-induced
thrombocytopenia, thrombosis, or mechanical events)
were checked within daily progress records.

2.7. Outcome
The primary outcome of this study was to assess advantages
of ECCO2R therapy over conventional treatment alone in
terms of 28-day ICU survival, iMV duration, and LOS.
2.8. Statistical analyses
A power analysis was performed with a free software
(G*Power v: 3.1.9.4, Germany) before the data collection,
that at least 44 ECOO2R patients were required in order
to gain an approximated power of 80% with 0.5 effect
size, 0.05 alpha error probability, and 2.0 critical t-value
in two tailed calculations. Collected data management
and analyses were performed using statistical software
program SPSS (IBM, SPSS Statistics v: 25.0, IL, USA, 2017).
Comparability of the data was provided by stratum and
weighting. Continuous variables were reported as median
and inter quartile range (IQR), mean ± standard deviation
(SD) and categorical variables as counts and proportions
when appropriate. Comparison of proportions was made
using Chi-square test. Data at different times during
ECCO2R (repeated measures) were compared using
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ICU Patients
(n=1715)

Excluded
(n=44)

Study sample
(n=395)

Excluded
(n=75)

ECCO2R
(n=31)

Surv. (n=21)
Ex (n=10)

Surv. (n=136)
Ex (n=109)

Conv. Treat.
(n=245)

COPD
(n=20)

Surv. (n=15)
Ex (n=5)

Surv. (n=10)
Ex (n=10)

COPD
(n=20)

Not matched
(n=131)

ARDS
(n=11)

Surv. (n=6)
Ex (n=5)

Surv. (n=2)
Ex (n=9)

ARDS
(n=11)

Not matched
(n=73)

Figure 2. Diagram representing secondary re-test procedure. Additional exclusions and best 1:1 matching process.
ICU; intensive care unit, ECCO2R; extracorporeal CO2 removal, COPD; chronic obstructive pulmonary disease,
ARDS; acute respiratory distress syndrome, conv. treat.; conventional treatment alone, surv.; survival.

analysis of variance (ANOVA). When significance (p ≤
0.05) obtained after 72 h of ECCO2R, was compared with
previous using paired t test (adjusted), and by Bonferroni
corrections. The conditional analyses were used rather
than unconditional since strata was relatively small. The
contingency tables were formed. Relative and absolute risk
reductions ((RRR and ARR), number need to treat (NNT),
and odds ratios (OR) were calculated. All P values were
two-tailed and values < 0.05 (CI of 95%) were deemed as
significant.
3. Results
Medical records of 1715 patients were scanned. After
exclusion of 164 patients with both COPD and ARDS
diagnoses, 395 patients who required iMV support due to
COPD (n = 256) or ARDS (n = 139) were assigned into the
study. The main reason for COPD admissions was acute
and severe exacerbation of disease (94%). ARDS was due
to primary pulmonary insults in 74% of the cases.
General characteristics, admission SOFA scores, ABG
and ventilatory parameters, iMV support duration, LOS
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and 28-day survival status of patients were presented
in Table 1. ECCO2R therapy was noted in 75 of 395
patients. ECCO2R group 28-day survival rate was 68%
and significantly higher than 58% survival rate of controls
(p = 0.025). In subgroup analyses, survival rates of COPD
(65%) and ARDS (73%) patient who received ECCO2R
therapy were higher than control COPD (55%) and ARDS
(65%) patients. In addition to this, ECCO2R therapy
significantly shortened iMV duration and ICU LOS in
both COPD and ARDS patients. Calculated total survival
OR was found below 2.0 (1.5 (0.9–2.6)), but NNT (NNT =
10), relative risk reduction (0.16 (0.03–0.39), and absolute
risk reduction rates (0.10 (0.02–0.21)) were promising for
ECCO2R therapy group, as presented in Table 2.
Arterial blood gas, ventilatory, clinical, and laboratory
parameters recorded at t = 0 and t = 72 of ECCO2R
procedure, and ECCO2R duration (days), pump flow
and sweep gas flow rates were presented in Table 3. The
pH, PaO2, and PaCO2 levels of the control group were
not significantly improved at t = 72. On the other hand,
ECCO2R therapy significantly ameliorated patients ABG
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Table 1. Presentation of COPD and ARDS patients’ general characteristics, SOFA scores, arterial blood gas and ventilatory parameters,
iMV days, LOS and 28-day survival rates. Frequency, percentage, median - IQR, and mean ± SD values were used as appropriate.
TOTAL (n = 395)

COPD (n = 256)

ECCO2R
(n = 75)

Control
(n = 320)

n, male/female

41/34

186/134

Age (years)

63 (17 - 93)

66 (16–97)

SOFA score

13 (8 - 17)

12 (7–16)

pH

7.156 ± 0.07

PaCO2 (mmHg)
PaO2 (mmHg)

ARDS (n = 139)

ECCO2R
(n = 49)

Control
(n = 207)

ECCO2R
(n = 26)

Control
(n = 113)

22/27

93/114

19/7

93/20

ns

68 (51–93)

69 (41–97)

ns

14 (8–17)

11 (7–16)

ns

58 (17–78)

64 (16–94)

ns

ns

14 (11–16)

14 (9–16)

ns

7.184 ± 0.02

ns

7.204 ± 0.05

7.235 ± 0.06

ns

7.133 ± 0.11 7.144 ± 0.18

ns

81 ± 21

77 ± 19

ns

61 ± 6

59 ± 7

ns

78 ± 21

75 ± 18

ns

86 ± 21

79 ± 18

ns

80 ± 6

78 ± 7

ns

56 ± 5

55 ± 7

ns

P/F ratio

89 ± 11

92 ± 12

ns

129 ±13

133 ± 14

ns

76 ±8

81 ± 9

ns

PEEP (cmH2O)

13 ± 3

Pplat (cmH2O)

36 ± 6

12 ± 3

ns

13 ±3

12 ± 4

ns

15 ±4

13 ± 5

ns

34 ± 7

ns

35 ±6

33 ± 5

ns

38 ±7

35 ± 6

ns

ΔP (cmH2O)

23 ± 2

22 ± 3

ns

22 ±2

21 ± 2

ns

23 ±4

22 ± 2

ns

Tv/PBW (mL/kg)

7±1

7±2

ns

7 ±1

7±1

ns

6 ±2

7±2

ns

iMV (days)

11 (8–19)

14 (7–22)

0.007

11 (7–18)

15 (8–21)

0.001

10 (8–17)

15 (9–25)

0.012

LOS (days)

17 (7–28)

26 (5–45)

0.032

17 (7–19)

21 (5–37)

0.035

15 (7–23)

29 (13–52)

0.025

32/17 (65%)

11 /94 (55%) 0.036

p

p

p

ABG

Ventilatory

Outcomes

n, survived/ex (%) 51 / 24 (68%) 187/133 (58%) 0.025

19/7 (73%) 74/39 (65%)

0.042

COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome, SOFA score; sequential organ failure
assessment score, iMV; invasive mechanic-ventilation duration, LOS; length of ICU stays, IQR; inter-quartile range, ABG; arterial blood
gas, P/F; PaO2/FiO2 ratio, PEEP; positive end expiratory pressure, Pplat; plateau pressure, ΔP; (driving pressure) = Pplat-PEEP, Tv/BPW;
tidal volume/predicted body weight, ECCO2R; extracorporeal CO2 removal.
Table 2. The 2x2 contingency table presenting 28-day survival statuses of ECCO2R vs. conventional treated-alone COPD and ARDS
patients, comparisons, and statistical calculations. Statistical p values, RRR, ARR, and ORs with 95% CIs.

TOTAL
COPD
ARDS

Survived (n)

Ex (n)

ECCO2R

51 (68%)

24 (32%)

Control

187 (58%)

133 (42%)

ECCO2R

32 (65%)

17 (35%)

Control

113 (55%)

94 (45%)

ECCO2R

19 (73%)

7 (27%)

Control

74 (65%)

39 (35%)

p

RRR

ARR

OR

NNT

0.025

0.16
(0.03–0.39)

0.10
(0.02–0.21)

1.5
(0.9–2.6)

10

0.036

0.20
(0.06–0.52)

0.11
(0.04–0.25)

1.6
(0.8–3.0)

9

0.042

0.12
(0.02–0.46)

0.08
(0.03–0.12)

1.4
(0.6–3.7)

13

ECCO2R; extracorporeal CO2 removal, COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome,
RRR; relative risk reduction, ARR; absolute risk reduction, NNT; number need to treat, OR; odds ratio, CI; confidence intervals.

parameters. Significant improvement in mean pH (p =
0.048) and PaO2 (p = 0.032), and significant reduction in
mean PaCO2 (p = 0.027) levels were provided at t = 72 of
ECCO2R treatment. While ventilatory parameters were
improved and facilitated LPV, the mean P/F ratio (p =

0.008), Pplat (p = 0.035) and driving pressure (p = 0.040)
were significantly improved in both COPD and ARDS
patients. A significant change in Tv/PBW levels were not
detected that were about 7 mL/kg throughout 72 h. Mean
PEEP levels were improved in COPD (p = 0.040) patients.
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Table 3. ECCO2R procedure recordings at t = 0 and t = 72 h of treatment; arterial blood gas, ventilatory, clinical and laboratory
parameter comparisons. Control group pH, PaCO2, and PaO2 levels were also presented, and no significant difference was noticed at t =
72. Data were presented as mean ± SD values, median-IQR, and statistical differences.
TOTAL (n = 75)
t=0

t = 72

COPD (n = 49)
p

t=0

t = 72

ARDS (n = 26)
p

t=0

t = 72

p

ABG
Case-pH

7.156 ± 0.07 7.339 ± 0.05 0.048

7.204 ± 0.05 7.355 ± 0.06 0.050 7.133±0.11 7.332 ± 0.05 0.045

Control-pH

7.184 ± 0.02 7.265 ± 0.09 ns

7.235 ± 0.06 7.289 ± 0.09 ns

Case-PaCO2 (mmHg)

81 ± 21

53 ± 9

0.027

78 ± 21

54 ± 10

0.030 86 ±21

52 ± 8

0.020

Control-PaCO2 (mmHg)

77 ± 19

71 ± 16

ns

75 ± 18

70 ± 17

ns

73 ± 14

ns

Case-PaO2 (mmHg)

61 ± 6

82 ± 8

0.032

80 ± 6

82 ± 8

0.040 56 ±5

83 ± 8

0.020

Control-PaO2 (mmHg)

59 ± 7

71 ± 9

ns

78 ± 7

80 ± 6

ns

61 ± 6

ns

P/F ratio

89 ± 11

150 ± 53

0.008

129 ± 13

166 ± 52

0.020 76 ± 8

142 ± 54

0.001

PEEP (cmH2O)

13 ± 3

12 ± 3

0.050

13 ± 3

10 ± 2

0.040 15 ± 4

16 ± 3

ns

Pplat (cmH2O)

36 ± 6

29 ± 3

0.035

35 ± 6

28 ± 4

0.030 38 ± 7

32 ± 2

0.050

ΔP (cmH2O)

23 ± 2

17 ± 3

0.040

22 ± 2

18 ± 3

0.040 23 ± 4

16 ± 3

0.040

Tv/PBW (mL/kg)

7 ±1

7±1

ns

7±1

7±2

ns

6±2

6±1

ns

RR (/min)

19 ± 2

18 ± 3

ns

16 ± 2

15 ± 3

ns

24 ± 3

25 ± 2

ns

HR (/min)

117 ± 13

113 ±13

ns

112 ± 15

108 ± 14

ns

127 ± 9

122 ± 11

ns

MAP (mmHg)

58 ± 9

54 ± 7

ns

58 ± 12

54 ± 8

ns

56 ± 6

52 ± 4

ns

Hemoglobin (g/dL)

11.3 ± 0.8

10.5 ± 0.8

0.050

11.6 ± 0.8

10.8 ± 0.6

0.050 10.7 ± 0.8

9.9 ± 1.1

0.050

PLT (10^3/µ)

117 ± 17

103 ± 18

0.043

121 ± 14

107 ± 19

0.040 109 ± 21

95 ± 17

0.050

PT-INR

1.3 ± 0.2

1.4 ± 0.2

ns

1.3 ± 0.2

1.4 ± 0.2

ns

1.2 ± 0.2

ns

aPTT ratio (s)

37 ± 8

73 ± 15

0.023

34 ± 8

68 ± 14

0.020 42 ± 9

85 ± 18

0.030

7.133 ±0.11 7.246 ± 0.11 ns
79 ±18
55 ±7

Ventilatory

Clinical

Laboratory

1.1 ± 0.2

ECCO2R
ECCO2R days

6 (4–9)

7 (4–9)

6 (4–8)

Pump flow (mL/min)

270 (190–420)

270 (180–420)

320 (210–450)

7 (6–10)

8 (6–12)

Sweep gas flow rate (L/min) 8 (6–11)

ECCO2R; extracorporeal CO2 removal, IQR; inter-quartile range, COPD; chronic obstructive pulmonary disease, ARDS; acute
respiratory distress syndrome, ABG; arterial blood gas, P/F; PaO2/FiO2 ratio, PEEP; positive end expiratory pressure, Pplat; plateau
pressure, ΔP; (driving pressure) = Pplat - PEEP, Tv/BPW; tidal volume/predicted body weight, RR; respiratory rate, HR; heart rate, MAP;
mean arterial pressure, ns; nonsignificant.

While in ARDS patients, required PEEP levels were not changed in 72 h. possible due to prolonged need for higher PEEP
levels in those patients.
There were no detected significant change or deterioration in patients’ mean RR, HR, and MAP parameters through
72 h. of ECCO2R therapy. The mean hemoglobin and PLT levels were found lower at t = 72 but those were not clinically
remarkable nor required transfusion, as in daily progress records. The aPPT ratio was 2× longer due to provided heparin
anti-coagulation protocol, at t = 72. No severe adverse effects related to procedure were mentioned in the records.
At the final step, we re-tested the hypothesis with a strict 1:1 matching by SOFA disease severity score. While 44
patients from ECCO2R and 75 patients from control group were excluded by additionally re-defined criteria, downsized
the case and control samples to 31/31 (COPD n = 20/20, ARDS n = 11/11). Figure 2. Total survival rates were in favor
of ECCO2R patients (68%) against controls (56%). In subgroup comparisons, survival rates of ECCO2R treated COPD
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(75%) and ARDS (55%) patients were significantly
higher than control COPD (50%) and ARDS (18%). The
contingency calculations for matched comparisons were
presented in Table 4. Although resulted sample size was
highly downsized by this strict matching, total survival
OR (1.7 (0.8–3.7)) and NNT (NNT = 8) values strikingly
favored beneficial effect of ECCO2R therapy.

more similar to our study patients, hence we assume those
results were more comparable than previous ones.
Eventually, the ECLAIR study in 2016 was published
that ECCO2R therapy was successful to avoid iMV and
shortened iMV duration, but not LOS nor improved
survival [15]. This was a multicentric case-control (n =
25/25) study that compared hypercapnic respiratory failure
patients, and especially focused on avoidance of intubation
and iMV by ECCO2R, rather than survival benefits. These
results were valuable but should be cautiously evaluated in
regards of small sample size for generalizability. Another
feasibility study on ECCO2R therapy in ARDS patients (n
= 15) by Fanelli et al., reported significant improvements
in clinical, ventilator, and ABG parameters similar to
our results. They underlined the efficiency of ECCO2R
in providing LPV, that was accounted as one of the most
effective approaches in ARDS patient [16]. Fanelli’s study
ARDS sample was also quite similar to our ARDS patients
in terms of age, sex, and SOFA scores, and were consistent
with our results.
Here, we also presented that 72 h of ECCO2R procedure
significantly improved ABG and ventilatory parameters in
both COPD and ARDS patients and safely provided LPV
settings. Thereby, we assumed this was the main influential
factor for higher survival rates. Another supportive study
by Hilty et al. assessed 20 ARDS and COPD patients with
hypercapnic respiratory failure, although a conventional
controls arm was not present, also reported that ECCO2R
therapy was safe and provided LPV [25]. Another similar
retrospective observational ECCO2R study by Moss et
al. that included 14 patients (COPD n = 5, ARDS n = 9)
with hypercapnic respiratory failure, compared the data
of survivors vs. nonsurvivors [26]. The mean pH levels
were successfully improved, and the survival rate was 71%
(10/14), in concordance with our results. However, the
average LOS (31.9 vs. 7) and iMV (53 vs. 8.5) were longer
in survivors than nonsurvivors. That discrepancy could be

4. Discussion
Recently, ECCO2R therapy has been more frequently
used in treatment of patients with severe respiratory
failure. Especially in conditions such as ARDS and acute
exacerbations of COPD that LPV is required and lifesaving.
ECCO2R facilitates settings of lower respiratory rates, and
lower driving and plateau pressures, while successfully
removing excess CO2. Additionally, removal of excess
CO2 also would help to normalize acidotic pH levels and
improve manageability of distressed conditions.
However, in a previous systematic review that included
two RCT and 12 observational studies on ARDS patients
(n = 495), ECCO2R therapy was not found advantageous
in terms of patient survival and LOS [23]. On the contrary,
our study results showed a significant survival and LOS
benefit with ECCO2R therapy. We assumed that difference
was related to mixed type of diagnoses in our study, in which
ARDS patients constituted the one third of the sample. It
was also reasonable to expect lower survival rates in ARDS
patients than COPD. Nevertheless, subgroup analyses of
our ARDS patients presented higher survival benefit with
ECCO2R. In addition, iMV duration and ICU LOS were
significantly shorter. Then, a supportive systematic review
to our assumptions, in 2015 by Sklar et al., that included
ten case series of ECCO2R therapy in COPD patients
with hypercapnic respiratory failure (n = 87), showed that
ECCO2R therapy assisted successful extubation (53%)
with lower mortality rates, and improved ABG parameters
[24]. The patient characteristics of Sklar’s sample were

Table 4. The 2x2 contingency table presenting 28-day survival statuses of ECCO2R vs. conventional treated-alone COPD and ARDS
patients, for 1:1 matching. Statistical p values, RRR, ARR, and ORs with 95% CIs.

TOTAL
COPD
ARDS

Survived (n)

Ex (n)

ECCO2R

21 (68%)

10 (32%)

Control

136 (56%)

109 (44%)

ECCO2R

15 (75%)

5 (25%)

Control

10 (50%)

10 (50%)

ECCO2R

6 (55%)

5 (45%)

Control

2 (18%)

9 (82%)

p

RRR

ARR

OR

NNT

0.018

0.22
(0.07–0.60)

0.12
(0.05–0.30)

1.7
(0.8–3.7)

8

0.016

0.50
(0.10–1.49)

0.25
(0.04–0.54)

3.0
(0.8–11.4)

4

0.021

2.0
(0.2–10.7)

0.36
(0.09–0.74)

5.4
(0.8–37.5)

3

ECCO2R; extracorporeal CO2 removal, COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome,
RRR; relative risk reduction, ARR; absolute risk reduction, NNT; number need to treat, OR; odds ratio, CI; confidence intervals.
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due to lack of a conventional treatment control group for a
coherent comparison in that study.
However, in 2017, Taccone et al. reviewed six studies
on ECCO2R therapy in COPD and ARDS patients (n
= 142) those were published between 1994–2015, and
concluded that evidence of survival benefit was moderate,
yet [7]. Although inconclusive data have been published
until 2018, we think these should be considered at respect
of that most studies were case series, not homogenous with
possible case-mix bias issues and lack of control groups.
As of 2018, more promising results have given to rise. A
UK Register study on severe respiratory failure patients (n
= 60) reported significant benefits of ECCO2R treatment
on ABG and ventilatory parameters, without any clinical
deterioration, however not showed an exact benefit for
survival [27]. Proceeded by Schmidt et al., 20 ARDS
patients treated by ECCO2R and safely enhanced LPV
with significantly higher survival rates (85%) [14]. Finally,
the recent SUPERNOVA study on feasibility of ECCO2R
therapy in 95 ARDS patients reported significantly high
cumulative 28-day survival rates (73%) [13]. In addition,
a recently published retrospective data of 11 respiratory
failure patients by Grasselli et al. reported that low-flow
VV-ECCO2R successfully improved ABG parameters
and reduced ventilatory load, with a 71% survival rate in
COPD patients [28].
The results of our study have supported and in
concordance with accumulated data as of 2018, but not
previous ones [13,14,28]. A positive attitude has been
rising on extra-corporeal therapies by 2018. Technological
advancements, procedural improvements, and easier
accessibility of ECCO2R should has contributed to this
trend. Promising benefits of ECCO2R has gained a wider
recognition and concern. Recently, the first European
consensus encouraging ECCO2R therapy in ICU has
been published by Combes et al., based on accumulated
data that ARDS and COPD patients could benefit from

ECCO2R [18]. As soon, we could anticipate that ECCO2R
would be a part of conventional treatment protocols in
severe ARDS and COPD patients.
Our study has number of limitations to be considered.
The retrospective design was prone to recall and selection
biases. The main analyses were depended on case-mix
samples. The secondary analyses with strict matching
provided a specific comparability but led high number of
exclusions and downsized the sample. These could have
produced exaggerated statistical significances. Finally, this
study represents to our patient population and applicable
to our settings, reasonably cannot be extrapolated to all
settings and external validations are required for decisive
evidence.
5. Conclusion
Results of our study supported that low-flow VV-ECCO2R
therapy has a role in improving survival rates, iMV
duration, and LOS in patients with HRF due to COPD or
ARDS. In addition, significant improvements in ABG and
ventilation parameters while facilitating LPV have been
achieved by ECCO2R therapy, with no marked clinical
and laboratory deteriorations. Further studies are required
to assess that promising benefits of ECCO2R therapy.
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